Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02376036 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of MGD010 in Healthy Subjects
A Phase 1 study of Healthy Subjects, sponsored by MacroGenics.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
- 1
- Study location
NCT02376036 is a Phase 1 study of Healthy Subjects that has completed, run by MacroGenics. The registered enrollment target is 73 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02376036, a Phase 1 study of Healthy Subjects, has completed, sponsored by MacroGenics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of this Phase 1 study is to assess the safety and tolerability of one MGD010 intravenous (IV) infusion in healthy adult volunteers.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Hepatitis A vaccine
- DRUG MGD010
Study Locations (1)
Maryland
- PAREXEL Baltimore Early Phase Clinical Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02376036
The ClinicalTrials.gov registry entry for NCT02376036 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (43% lower). The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02376036 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02376036 about?
NCT02376036 is a clinical study titled "Phase 1 Study of MGD010 in Healthy Subjects". The primary goal of this Phase 1 study is to assess the safety and tolerability of one MGD010 intravenous (IV) infusion in healthy adult volunteers.
What is the current status of trial NCT02376036?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2015-02. Estimated completion is 2017-02.
What conditions does trial NCT02376036 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT02376036?
The interventions under investigation include: Placebo (DRUG), Hepatitis A vaccine (BIOLOGICAL), MGD010 (DRUG).
Who is sponsoring clinical trial NCT02376036?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02376036 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.